Clinical Trial

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and safety of precision therapy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-11-21; most recent amendment 2026-03-27.
Trial Details
NCT Number NCT06145308
Lead Sponsor Peking Union Medical College
Collaborators: Peking University Hospital of Stomatology
Conditions Salivary Gland Carcinoma, Precision Therapy
Enrollment 39 participants
Start Date 2023-08-15
Primary Completion 2028-07-10 (estimated)
Study Completion 2028-07-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-02